AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15116260
Drug: Pravastatin (HMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (HMG CoA reductase inhibitor)
Trial: 11603956
Drug: Copper dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper dose of 2 mg Cu/L
Trial: 11603956
Drug: Copper dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper dose of 4 mg Cu/L
Trial: 11603956
Drug: Copper dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper dose of 6 mg Cu/L
Trial: 11603956
Drug: Copper dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper dose of 8 mg Cu/L
Trial: 11603956
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 mg Cu/L)
Trial: 9557622
Drug: Influenza virus
RxNorm normalized name: Influenza virus Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza virus vaccine (1996-1997)
Trial: 9557622
Drug: B/T lymphocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B/T lymphocyte ratio during chemotherapy
Trial: 11271343
Drug: Long-term steroid
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term steroid therapy (0.1 mg/kg per day)
Trial: 2651949
Drug: Furosemide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (200 mg IV every 6 hours for 4 days)
Trial: 2651949
Drug: Furosemide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (200 mg IV every 6 hours) with dopamine (1 microgram/kg/min for 4 days)
Trial: 1124717
Drug: Propranolol (increasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (increasing doses)
Trial: 23639514
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (DEX, 0.5 μg/kg; n = 18)
Trial: 21286241
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg nightly (n = 17)
Trial: 17061999
Drug: FTY720 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 5.0 mg plus reduced-dose cyclosporine (RDC)
Trial: 17061999
Drug: FTY720 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 5.0 mg
Trial: 15055565
Drug: Olopatadine 0.2%
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.2% solution
Trial: 8833678
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment approaches
Trial: 2414023
Drug: Cisplatinum and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatinum and Bleomycin (combined treatment)
Trial: 29158011
Drug: Extended intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended intermittent letrozole (2.5 mg/day orally for 9 months followed by a 3-month break in years 1-4 and then 2.5 mg/day during all 12 months of year 5)
Trial: 29158011
Drug: Continuous letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous letrozole (2.5 mg/day orally for 5 years)
Trial: 28453454
Drug: Intra-articular hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronate and tramadol injection
Trial: 28453454
Drug: Intra-articular hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronate injection alone
Trial: 18328348
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rosiglitazone (RSG) 4 mg/d (increased to 8 mg/d after 6 months) plus glibenclamide
Trial: 17139601
Drug: Prostanoids, endothelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostanoids, endothelin receptor antagonists, or phosphodiesterase 5 inhibitors
Trial: 17139601
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of underlying disease
Trial: 14971794
Drug: Phentolamine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine 0.2 mg kg(‐1) i.v.
Trial: 31987228
Drug: S. officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. officinalis extract (330 mg daily for 8 weeks)
Trial: 24177170
Drug: No pre‐treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre‐treatment (NS, control) with DMG LUXACORE Smartmix Dual
Trial: 19352324
Drug: VEGF gene
RxNorm normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VEGF gene therapy (2,000 microg of VEGF plasmid DNA)
Trial: 19352324
Drug: VEGF gene
RxNorm normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VEGF gene therapy
Trial: 17445644
Drug: Prophylactic low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic low-molecular-weight heparin for 1 week (Group 2)
Trial: 17445644
Drug: Conventional heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional heparin for 1 week (Group 3)
Trial: 17445644
Drug: Conventional heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional heparin (Group 3)
Trial: 15878544
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) followed by acenocoumarol
Trial: 26648706
Drug: Fluticasone propionate/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/formoterol (two doses)
Trial: 23289773
Drug: Psychological preoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological preoperative program (group 1) including psychological preparation activities and psychologist's support during all phases of the operatory iter.
Trial: 17530622
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy intervention
Trial: 12614418
Drug: Three treatments
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three treatments with cooled 40‐ms alexandrite laser (fluences of 16 to 24 J/cm2)
Trial: 12614418
Drug: Two treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two treatments with cooled 40‐ms alexandrite laser (fluences of 16 to 24 J/cm2)
Trial: 12614418
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment with cooled 40‐ms alexandrite laser (fluences of 16 to 24 J/cm2)
Trial: 1998281
Drug: Questran Light
RxNorm normalized name: Questran Light
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Questran Light (4 g of cholestyramine in 5 g of powder per pack)
Trial: 1998281
Drug: Questran (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Questran (4 g of cholestyramine in 9 g of powder per pack)
Trial: 31075171
Drug: Artesunate therapy
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate therapy
Trial: 24254301
Drug: Functional beverage
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional beverage (FB) consumed 187 mL acutely and twice a day for 15 days chronically
Trial: 20852059
Drug: Biventricular pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biventricular pacing with peri-infarct LV lead placement (cardiac resynchronization therapy [CRT]-D)
Trial: 9125457
Drug: Linear acceleration
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linear acceleration steps of 0.05 g, 0.1 g, or 0.24 g amplitude
Trial: 2576366
Drug: Picumast dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picumast dihydrochloride (2 mg twice daily orally)
Trial: 2576366
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg twice daily orally)
Trial: 26627982
Drug: Corticosteroids (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (IV or PO administration totaling more than 20 mg methylprednisolone equivalents during one calendar day)
Trial: 16945121
Drug: Silodosin 4
RxNorm normalized name: silodosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 4 mg twice daily (severe symptoms subgroup)
Trial: 27166233
Drug: Zolpidem CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem CR 12.5 mg
Trial: 18566972
Drug: i.v. placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. placebo administration with glucose expectation
Trial: 15772863
Drug: 19-mg caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 19-mg caffeine and 250-mg theobromine
Trial: 7478687
Drug: Sterile Water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Water Injections (SWI)
Trial: 7478687
Drug: Saline Injections
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline Injections (PSI)
Trial: 28389217
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of octopamine
Trial: 21788663
Drug: Idebenone 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idebenone 900 mg/day
Trial: 10690882
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE; 0.625 mg daily)
Trial: 10690882
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg daily) plus CEE (0.625 mg daily)
Trial: 9350365
Drug: Thiamylal 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamylal 5 mg.kg-1 with inhalation of 100% oxygen (Group C)
Trial: 1443509
Drug: Racemic ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic ketamine 2 mg/kg bw
Trial: 1443509
Drug: S-(+)-ketamine 1
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-(+)-ketamine 1 mg/kg bw
Trial: 1443509
Drug: S-(+)-ketamine 1
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-(+)-ketamine 1 mg/kg bw with midazolam 0.1 mg/kg i.v.
Trial: 2422103
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus aprotinin (10,000 KIU for every 10 U.I. insulin)
Trial: 2422103
Drug: Insulin by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin by itself
Trial: 26707592
Drug: Fostamatinib 200
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib 200 mg BID
Trial: 26707592
Drug: Fostamatinib 100
RxNorm normalized name: fostamatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 100 mg BID
Trial: 22196968
Drug: 1-year treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-year treatment: induction: IFN alfa-2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks, maintenance: IFN alfa-2b, 10 MU (flat dose), SC, 3 days/week for 12 months (n = 285)
Trial: 22196968
Drug: 2 years
RxNorm normalized name: Childrens Panadol 5 - 12 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 years of same treatment as Arm B (n = 285)
Trial: 15316947
Drug: Two-step off-drug
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two-step off-drug QT correction analysis
Trial: 15316947
Drug: One-step off-
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step off- and on-drug QT analysis
Trial: 11139800
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin 5000 units subcutaneously every 8 hours
Trial: 11139800
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg subcutaneously daily
Trial: 8396082
Drug: Comparator agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator agents (co-amoxiclav, amoxycillin, penicillin V, erythromycin, dicloxacillin, flucloxacillin)
Trial: 29924907
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of meglumine antimoniate (20 mg SbV/kg/day for 20 days) and oral tamoxifen (40 mg/day for 20 days)
Trial: 29924907
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of meglumine antimoniate (20 mg SbV/kg/day for 20 days) and topical tamoxifen (0.1% tamoxifen citrate for 20 days)
Trial: 29924907
Drug: Standard meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard meglumine antimoniate (20 mg/kg/day for 20 days)
Trial: 27084921
Drug: Isavuconazole (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole (20, 40, or 60 mg/kg every 24 h after a 90 mg/kg loading dose for 12 days)
Trial: 27084921
Drug: Isavuconazole (clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole (clinical dosing regimen)
Trial: 25420830
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid therapy (Group B)
Trial: 9574332
Drug: Automatic pen
RxNorm normalized name: AMMONIA,AROMATIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automatic pen for subcutaneous injections of low molecular heparin
Trial: 8365195
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg beta-carotene and 25,000 IU vitamin A as retinyl palmitate (intervention)
Trial: 18840077
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg single dose of orally administered fluconazole
Trial: 18840077
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of orally administered fluconazole once per day for 2 weeks
Trial: 11379466
Drug: Griseofulvin 500
RxNorm normalized name: griseofulvin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin 500 mg daily for 10 days
Trial: 29514317
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (Nicoderm 14 mg)
Trial: 29514317
Drug: Nicotine spray
RxNorm normalized name: nicotine Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine spray (Nicotrol, 2 × 1 mg/trial)
Trial: 29514317
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch plus placebo spray
Trial: 25790943
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg slow‐release isosorbide‐5-mononitrate (ISMN)
Trial: 16279258
Drug: Lung-volume-reduction surgery
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung-volume-reduction surgery (LVRS) plus medical treatment
Trial: 9329348
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg hydrocortisone
Trial: 3525386
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir plus 5% acyclovir cream
Trial: 3525386
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir plus matching placebo cream
Trial: 28566441
Drug: Weekly Jintrolong
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly Jintrolong (0.2 mg/kg/week)
Trial: 28566441
Drug: Daily rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rhGH (0.25 mg/kg/week)
Trial: 23474384
Drug: Preference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference group (varied treatments)
Trial: 21937848
Drug: Astaxanthin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin supplementation (3 mg/day) for 4 or 12 weeks
Trial: 21937848
Drug: Astaxanthin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin supplementation (1 mg/day)
Trial: 19430742
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two antihistamines (levocetirizine 10 mg/fexofenadine 360 mg)
Trial: 19430742
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of three antihistamines (levocetirizine 10 mg/fexofenadine 360 mg/azelastine 4 mg)
Trial: 19430742
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage desloratadine (20 mg)
Trial: 16377455
Drug: Parallel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parallel treatment
Trial: 9564642
Drug: GnRH‐a (buserelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐a (buserelin acetate, 600 μg/d for six weeks) plus hMG (conventional doses for 14 cycles)
Trial: 9564642
Drug: Low-dose hMG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hMG (for 17 cycles)
Trial: 782146
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage heparin
Trial: 31623498
Drug: Rivaroxaban (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (20 mg/d) following ROCKET AF criteria
Trial: 31623498
Drug: Rivaroxaban (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (15 mg/d) following J-ROCKET AF criteria
Trial: 31623498
Drug: Rivaroxaban (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (15 mg/d) following ROCKET AF criteria
Trial: 31623498
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg/d) following J-ROCKET AF criteria
Trial: 31623498
Drug: Rivaroxaban (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (20 mg/d) and (15 mg/d)
Trial: 29132740
Drug: Symbiotics (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotics (12 g/day of Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium bifidum, and fructooligosaccharides)
Trial: 29132740
Drug: Medium absorption
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium absorption complex carbohydrate
Trial: 23328338
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol (0.1 g tid) for 3 days followed by oral tramadol (0.1 g tid) for 4 days
Trial: 23328338
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib (40 mg bid) for 3 days followed by oral celecoxib (0.2 mg bid) for 4 days
Trial: 23328338
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib (40 mg bid) for 3 days
Trial: 23328338
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol (0.1 g tid) for 3 days
Trial: 17702193
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of nifuratel
Trial: 17702193
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of nifuratel
Trial: 15025738
Drug: Levosimendan at
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan at 0.05 micro g kg(‐1) min(‐1)
Trial: 15025738
Drug: Levosimendan at
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan at 0.1 micro g kg(‐1) min(‐1)
Trial: 9734737
Drug: Amino acids,
RxNorm normalized name: AMINO ACIDS, SOY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acids, glucose, and lipid infusion for 3 hours
Trial: 8291598
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin 0.3% eyedrops, six times, one drop every three hours until 90 minutes preoperatively
Trial: 8291598
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin 0.3% eyedrops, two additional instillations, one drop every 30 minutes until 30 minutes before aspiration
Trial: 8291598
Drug: Oral ofloxacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin, single 200‐mg dose
Trial: 8291598
Drug: Intravenous ofloxacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ofloxacin, 200 mg infusion
Trial: 30783328
Drug: Heparin topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin topical solution (1000 IU/ml)
Trial: 30783328
Drug: Heparin topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin topical gel (200 IU/g)
Trial: 24910102
Drug: Ketamine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (all doses)